Paragon buys Innere Medizin from UCB

Paragon drew equity for the transaction from its €412m buyout fund, which held a final close in July 2014. The GP is currently preparing to come back to market with its third fund, Unquote understands. 

Innere Medizin had been operating as a separate business entity from its parent since March 2016. UCB said the divestment will enable the parent group to focus on its core activities of neurology, immunology and the treatment of bone diseases.

Paragon will rebrand the business and the new name will be announced after the closing of the transaction.

Company
Innere Medizin is headquartered in Monheim am Rhein and employs 200 people. The company focuses on promoting pharmaceutical products to GPs and specialists in cardiovascular and respiratory diseases in Germany.

People
Paragon Partners – Edin Hadzic (partner).

Advisers
Vendor – DC Advisory (corporate finance); Hengeler Mueller (legal).
Acquirer – Ebner Stolz (legal, tax, financial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• Germany
• Paragon Partners GmbH